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O B J E C T I V E S The aim of this study was to determine the 2-year prognostic value of cardiac
computed tomography (CT) for predicting major adverse cardiac events (MACE) in patients presenting
to the emergency department (ED) with acute chest pain.
B A C KG ROUND CT has high potential for early triage of acute chest pain patients. However, there
is a paucity of data regarding the prognostic value of CT in this ED cohort.
METHOD S We followed 368 patients from the ROMICAT (Rule Out Myocardial Infarction Using
Computer Assisted Tomography) trial (age 53 12 years; 61% male) who presented to the ED with acute
chest pain, negative initial troponin, and a nonischemic electrocardiogram for 2 years. Contrast-
enhanced 64-slice CT was obtained during index hospitalization, and caregivers and patients remained
blinded to the results. CT was assessed for the presence of plaque, stenosis (50% luminal narrowing),
and left ventricular regional wall motion abnormalities (RWMA). The primary endpoint was MACE,
deﬁned as composite cardiac death, nonfatal myocardial infarction, or coronary revascularization.
R E S U L T S Follow-up was completed in 333 patients (90.5%) with a median follow-up period of 23
months. At the end of the follow-up period, 25 patients (6.8%) experienced 35 MACE (no cardiac deaths,
12 myocardial infarctions, and 23 revascularizations). Cumulative probability of 2-year MACE increased
across CT strata for coronary artery disease (CAD) (no CAD 0%; nonobstructive CAD 4.6%; obstructive
CAD 30.3%; log-rank p  0.0001) and across combined CT strata for CAD and RWMA (no stenosis or
RWMA 0.9%; 1 feature—either RWMA [15.0%] or stenosis [10.1%], both stenosis and RWMA 62.4%;
log-rank p 0.0001). The c statistic for predicting MACE was 0.61 for clinical Thrombolysis In Myocardial
Infarction risk score and improved to 0.84 by adding CT CAD data and improved further to 0.91 by
adding RWMA (both p  0.0001).
CONC L U S I O N S CT coronary and functional features predict MACE and have incremental prog-
nostic value beyond clinical risk score in ED patients with acute chest pain. The absence of CAD on CT
provides a 2-year MACE-free warranty period, whereas coronary stenosis with RWMA is associated with
the highest risk of MACE. (J Am Coll Cardiol Img 2011;4:481–91) © 2011 by the American College of
Cardiology Foundation
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482oronary artery disease (CAD) is a leading
cause of morbidity and mortality in the
developed world (1). Multidetector car-
diac computed tomography (CT) angiog-
aphy has been well established as an accurate
oninvasive modality to evaluate for CAD (2–6).
ecent studies have examined the prognostic utility
f CT in patients with known or suspected CAD
or predicting major adverse cardiac events
MACE) and mortality (7–13). Not surprisingly,
See page 492
these CT studies showed that patients with severe
CAD, such as significant stenosis or multivessel
disease, had a higher risk of a worse outcome. These
long-term studies, however, were from retrospective
observational cohorts in which the CT results were
used to guide management.
Acute chest pain is a common symptom
among emergency department (ED) pa-
tients and remains a diagnostic challenge
(14), especially when the findings on the
initial electrocardiograms and cardiac bio-
markers are normal. The ROMICAT
(Rule Out Myocardial Infarction Using
Computer Assisted Tomography) trial
was a prospective, double-blind observa-
tional study that included 368 ED patients
with acute chest pain and a low to inter-
mediate risk of acute coronary syndrome
(ACS) (15). In the ROMICAT trial, 50%
of ED patients had no evidence of coro-
nary atherosclerosis on CT and did not
have ACS during the index hospitalization
or MACE at 6 months (15). Thus, a normal
finding on CT without evidence of any coronary
atherosclerosis may allow earlier triage and change
the future disposition decision of ED physicians in
this patient population (16). Furthermore, CT
could newly identify a subgroup of patients with
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December 17, 2010; accepted December 20, 2010.coronary artery stenosis in the absence of ACS who
may be restratified as at high risk of future cardio-
vascular events.
Although CT has great potential for use to triage
ED patients, the prognostic outcome in this patient
cohort is not known. Thus, we sought to assess the
prognostic utility of cardiac CT coronary and func-
tional features for predicting MACE in ED patients
with acute chest pain from the ROMICAT trial.
M E T H O D S
Patient selection. We followed the 368 enrolled
patients from the ROMICAT trial for 2 years (6
months) after the index hospitalization. These pa-
tients were enrolled from May 2005 to May 2007
and had an initial chief symptom of acute chest pain
lasting 5 min during the 24-h period before the
index hospitalization as well as normal initial tro-
ponin levels and electrocardiographic findings. De-
tails regarding the inclusion and exclusion criteria
were previously reported (15). Briefly, during the
index hospitalization, all subjects underwent a stan-
dard contrast-enhanced coronary CT study before
admission to the hospital. Both caregivers and patients
remained blinded to the results of cardiac CT. The
institutional review board approved the study proto-
col, and all patients provided written informed
consent.
Coronary CT angiography image acquisition. CT im-
ging was performed using a 64-slice CT scanner
Sensation 64, Siemens Medical Solutions, Forch-
eim, Germany). Unless contraindications were
resent, patients received 0.6 mg of sublingual
itroglycerin and if the heart rate was 60 beats/
in intravenous beta-blocker (5 to 20 mg meto-
rolol) in preparation for the scan. Per standard
rotocol, a test bolus of 20 ml of contrast agent was
dministered at a flow rate of 5 ml/s to determine
he optimal timing of contrast injection. Coronary
T datasets were acquired with 64  0.6-mm slice
ollimation, a gantry rotation time of 330 ms, tube
oltage of 120 kV, and an effective tube current of
50 mA using electrocardiogram-correlated tube
urrent modulation in 46% of cases. Contrast agent
80 to 100 ml, iodixanol 320 mg/cm3, Visipaque,
E Healthcare, Princeton, New Jersey) was in-
ected intravenously at a rate of 5 ml/s to ensure
omogeneous enhancement of the entire coronary
rtery tree. For coronary assessment, axial images
ere reconstructed with a slice thickness of 0.75
m and increment of 0.4 mm using a retrospec-B B R E V I A T I O N S
N D A C R O N YM S
ACS acute coronary
syndrome(s)
CT computed tomograph
ED emergency departmen
LV left ventricular
MACEmajor adverse card
event(s)
NSTEMI non–ST-segment
elevation myocardial infarct
RWMA regional wall moti
abnormalities
TIMI Thrombolysis Inively electrocardiogram-gated half-scan algorithm
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483with a temporal resolution of 165 ms. For func-
tional analysis, 10 datasets of axial images were
reconstructed for every 10% of the R-R interval
from 5% to 95% with a slice thickness of 1.5 mm
and increment of 1.5 mm. All reconstructions were
transferred to an offline workstation for analysis
(Leonardo, Siemens Medical Solutions).
Coronary atherosclerotic plaque and stenosis assessment.
The presence of nonobstructive coronary athero-
sclerotic plaque per segment, either calcified or
noncalcified, was determined as described previ-
ously, using a modified 17-segment model of the
coronary artery tree (17,18). Patients were stratified
based on the presence and severity of CAD into no
CAD, nonobstructive CAD, and obstructive CAD.
Obstructive CAD was defined either as coronary
artery stenosis with 50% luminal diameter ob-
struction or if coronary stenosis could not be ex-
cluded (n  34) and deemed inconclusive.
Regional left ventricular function assessment. Re-
gional wall motion abnormalities (RWMA) were
assessed qualitatively based on the American Heart
Association/American College of Cardiology 17-
segment model, as previously described in the
functional dataset (19,20). Briefly, functional anal-
ysis was assessed by viewing the left ventricle
throughout the entire cardiac cycle in a cine mode
and in standard cardiac orientations used in echo-
cardiography (4-chamber, 2-chamber, and left ven-
tricular [LV] short-axis). RWMA had to be present
in at least 2 contiguous myocardial segments or in 1
segment visualized in 2 different views to be con-
sidered a true positive finding. Each LV segment
was classified as having either normal or abnormal
(hypokinetic, akinetic, dyskinetic, or aneurysmal)
function (21). Patients in whom RWMA could not
be assessed due to an incomplete LV function study
(n  12) were classified as having no RWMA.
Endpoints. The primary endpoint was MACE dur-
ng the 2-year follow-up period. MACE was de-
ned as cardiac death, ST-segment elevation myo-
ardial infarction (STEMI), non–ST-segment
levation myocardial infarction (NSTEMI), or cor-
nary revascularization. Coronary revascularization
ncluded percutaneous coronary intervention (PCI)
nd coronary artery bypass graft surgery. An adju-
ication outcome panel of 2 physicians reviewed the
atient data forms and verified by review of medical
ecords to determine whether a patient had MACE
uring the follow-up period. The outcome panel
as blinded to the findings of the cardiac CT.
isagreement was resolved by consensus, whichncluded an additional senior cardiologist (22). tFollow-up. A follow-up telephone call was made to
administer a standardized questionnaire at 6 months
and 2 years (6 months) after enrollment to deter-
mine the occurrence of MACE. The telephone num-
bers were collected from the patients at the time of the
index hospitalization. If the telephone numbers were
invalid, attempts were made to acquire current patient
contact details from our electronic medical records and
online telephone registries. Five attempts were made
using the patient’s direct phone number, after which 2
attempts were made to reach the emergency contact
person listed. If we were still unsuccessful, the primary
care physician was contacted. If direct contact was not
possible with either the patient or primary care phy-
sician, we reviewed the electronic medical records for
information regarding the defined endpoints within
the 2-year follow-up period. As a final step, we
searched the Social Security Death Index for all
patients 3 years after their enrollment in the trial. This
also included those individuals for whom the afore-
mentioned methods were not successful and whose
status remained unknown.
Statistical analysis. Continuous variables were ex-
ressed as mean  SD. Nominal variables were
xpressed as frequency and percentages. For con-
inuous variables, differences in means were assessed
ith Student t tests and analysis of variance, as
ppropriate. For categorical variables, differences in
roportions were compared using the Fisher exact
r chi-square test and the Mantel-Haenszel trend
est, as appropriate. Cumulative event rates as
tratified by CT features were estimated using the
roduct limit (Kaplan-Meier) methods and log-
ank test. Patients were censored after the first
vent, if not otherwise specified. Unadjusted and
djusted Cox proportional hazards models control-
ing for medication use at baseline and 2-year
ollow-up were used to evaluate the association of
ardiac CT findings for predicting MACE. In
ddition, Cox proportional hazards models were
sed to evaluate the prognostic value of the clinical
hrombolysis In Myocardial Infarction (TIMI)
nstable angina/NSTEMI risk score (23) and the
ddition of cardiac CT findings for predicting
ACE. The c-statistic, which is equivalent to the
rea under the receiver-operator characteristic curve
24), was determined to evaluate the prognostic
iscriminatory capacity for predicting MACE for
ach Cox model. The incremental prognostic value of
dding each cardiac CT finding beyond that of clinical
IMI risk score was determined by comparing the global
hi-square value of the models. We tested the propor-
ional hazards assumption using time-varying covariates
c
w
I
c
f
f
f
t
c
g
o
C
a
f
c
r
s
s
4
t
a
h
s
s
a
l
t
w
p
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 4 , N O . 5 , 2 0 1 1
M A Y 2 0 1 1 : 4 8 1 – 9 1
Schlett et al.
Prognostic Value of CT in Acute Chest Pain
484in all Cox regression models; no violations were observed
and all Cox regression models included only non–time-
dependent covariates. A 2-sided p value of 0.05 was
onsidered to indicate statistical significance. All analyses
ere performed using SAS software version 9.2 (SAS
nstitute Inc., Cary, North Carolina).
R E S U L T S
Patient characteristics. Figure 1 depicts the flow-
hart of the ROMICAT trial patients and their
ollow-up. Of the 368 patients, there was complete
ollow-up for 333 patients (90.5%). The median
ollow-up period was 23 months. The majority of
he patients (n  310, 84.2%) were followed up by
a standardized telephone call. In 23 patients (6.3%),
the 2-year follow-up was completed by using infor-
mation from a third party (emergency contact
person, n  2; primary care physician, n  2; and
medical records, n  19). In the remaining 35
patients (9.5%), we used the Social Security Death
Index. Overall, there was only 1 death, which was
due to noncardiac etiology (lymphoma) during the
follow-up period.
Table 1 shows the patient characteristics of the
entire ROMICAT trial cohort and comparison
among patients with complete follow-up and those
lost to follow-up. Patients in this trial were pre-
dominantly low risk, with 94.3% having a TIMI
risk score of 0 to 2 points. Although patients lost
to follow-up were all alive according to the Social
Security Death Index, they were younger and
Figure 1. Flow Chart of the ROMICAT Trial Follow-Up
*All patients underwent cardiac computed tomography during inde
the results throughout the study. **Patients were followed by stand
Index (SSDI). The SSDI search was performed in all patients 3 years
Computer Assisted Tomography.more frequently male and having diabetes melli-
tus, although less likely to have hyperlipidemia or
taking baseline cardiac medications than patients
with complete follow-up. When comparing CT
features, there was a trend for patients with more
severe CAD to have complete follow-up (p 
0.06), whereas no difference was seen regarding
RWMA (p  0.28). Table 2 shows the patient
haracteristics as stratified by CT coronary cate-
ories of no CAD, nonobstructive CAD, and
bstructive CAD. With increasing severity of
T-based CAD categories, patients were older
nd more likely to be men, had more cardiac risk
actors and higher TIMI risk scores, and taking
ardiac medications.
Cardiac CT ﬁndings. Table 1 shows CAD catego-
ies as determined by CT. When assessed by
tenosis, there were 300 patients (81.5%) with no
tenosis and 68 (18.5%) with stenosis. There were
6 patients (12.5%) with regional LV dysfunc-
ion. When stratified by CT coronary stenosis
nd functional categories, 280 patients (76.1%)
ad no stenosis or RWMA, 20 (5.4%) had no
tenosis but had RWMA, 42 (11.4%) had steno-
is without RWMA, and 26 (7.1%) had stenosis
nd RWMA. The effective radiation dose was
ower in patients scanned with electrocardiogram
ube current modulation (11.4  2.2 mSv) than
ithout (17.6  2.2 mSv) (p  0.0001).
Hard cardiac events. At the end of the follow-up
eriod, 25 patients (6.8%) had a total of 35 MACE
spitalization and the caregiver and patients remained blinded to
ized telephone call, a third party, and/or the Social Security Death
r enrollment. ROMICAT  Rule Out Myocardial Infarction Usingx ho
ard
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485(no cardiac deaths, 12 myocardial infarctions, 23
coronary revascularizations). During the first 30
days (acute phase), MACE developed in 20 patients
(1 STEMI, 7 NSTEMI, 16 PCI, and 2 coronary
artery bypass grafts). After this acute phase, MACE
developed in 5 more patients (1 STEMI, 3
NSTEMI, and 4 PCI). Of the 20 patients with
MACE during the acute phase, 1 patient with
initial NSTEMI treated with PCI had a recurrent
MACE (second PCI at 1.8 years after enrollment
for recurrent chest pain).
MACE as stratiﬁed by cardiac CT ﬁndings. Figure 2
epicts the Kaplan-Meier estimates of the cumula-
ive probability of MACE as stratified by CT
ndings; Table 3 provides the probability of events
t various time points. The probability of 2-year
ACE increased significantly across the strata of
T CAD categories (0% for patients without
AD, 4.6% for patients with nonobstructive CAD,
nd 30.3% for patients with obstructive CAD;
Table 1. Baseline Patient Characteristics of the Entire ROMICAT
and Those Lost From Follow-Up
Total Cohort
(N  368)
Demographics
Age, yrs 52.8 11.8
Male 226 (61.4)
Body mass index, kg/m2 29.0 6.0
Risk factors
Diabetes mellitus 40 (10.9)
Hypertension 145 (39.4)
Hyperlipidemia 135 (36.7)
Smoking 180 (48.9)
Family history of CAD 89 (24.2)
TIMI risks for UA/NSTEMI
0–2 points 347 (94.3)
3–4 points 20 (5.4)
5–7 points 1 (0.3)
Medications at baseline
Aspirin 117 (31.8)
Beta-blockers 84 (22.8)
Statins 103 (28.0)
ACE-I 56 (15.2)
Any of the above medications 204 (55.4)
Features of cardiac CT
CAD categories
No CAD 183 (49.7)
Nonobstructive CAD 117 (31.8)
Obstructive CAD 68 (18.9)
RWMA 46 (12.5)
Values are mean  SD or n (%).
ACE-I  angiotensin-converting enzyme inhibitor; CAD  coronary artery diseas
Thrombolysis In Myocardial Infarction; UA/NSTEMI  unstable angina/non–ST-segmog-rank p  0.0001). Patients with stenosis had a tearly 20-fold increase in the risk of MACE than
hose without stenosis, with MACE of 30.3%
ersus 1.8%, respectively (hazard ratio: 19.84, p 
.0001). As shown in Table 4, even after adjust-
ent for being on cardiac medications, patients
ith CT stenosis had a 16- to 21-fold increase in
isk of MACE than those without (both p 
.0001). With functional analysis added to CT
oronary categories (Table 3, Fig. 2), a gradient
tepwise increase was seen in the 2-year probability
or MACE in patients with no stenosis or RWMA
0.9%), followed by patients with only 1 feature
either stenosis [10.1%] or RWMA [15.0%]), high-
st in patients with both stenosis and RWMA
62.4%, log-rank p  0.0001). This confers to a
92-fold increase adjusted risk in MACE for
atients with both CT features of stenosis and
WMA and a 12-fold increase in adjusted -risk
or patients with either stenosis or RWMA com-
ared with patients without stenosis or RWMA as
l Cohort, Those With Complete Follow-Up,
Follow-up
(n  333)
Lost to Follow-up
(n  35) p Value
53.3 11.8 47.6 10.7 0.006
199 (59.8) 27 (77.1) 0.05
29.4 5.9 29.0 6.0 0.64
32 (9.6) 8 (22.9) 0.04
135 (40.5) 10 (28.6) 0.20
129 (38.7) 6 (17.1) 0.02
167 (50.2) 13 (37.1) 0.16
78 (23.4) 11 (31.4) 0.30
0.74
313 (94.0) 34 (97.1)
19 (5.7) 1 (2.9)
1 (0.3) 0 (0)
112 (33.6) 5 (14.3) 0.02
82 (24.6) 2 (5.7) 0.01
98 (29.4) 5 (14.3) 0.07
53 (15.9) 3 (8.6) 0.33
192 (57.7) 12 (34.3) 0.01
0.06
159 (47.8) 24 (68.6)
111 (33.3) 6 (17.4)
63 (18.9) 5 (14.3)
44 (13.2) 2 (5.7) 0.28
 computed tomography; RWMA  regional wall motion abnormalities; TIMI 
elevation myocardial infarction.Tria
e; CThe reference standard (Table 4).
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486Incremental prognostic value of cardiac CT ﬁndings.
Table 5 details the incremental value of adding both
CT coronary stenosis and functional findings be-
yond that of the clinical TIMI risk score for
predicting MACE. Both CT stenosis and RWMA
remained independently predictive of MACE,
whereas the clinical TIMI risk score was no longer
significant after adding in stenosis and/or RWMA.
The discriminatory capacity for predicting MACE
improved from a c-statistic of 0.61 with the clinical
TIMI risk score alone to 0.84 when CT stenosis
was added (p 0.0001), which further improved to
0.91 with the addition of RWMA (p  0.0001).
Late MACE after 30 days. For patients without
ACE during the acute phase (Fig. 3), the esti-
ated 2-year event rate for late MACE (30 days)
ncreased across CAD categories as determined by
T (0% for no CAD, 1.2% for nonobstructive
AD, and 8.9% for obstructive CAD; log-rank p
.0003). In these patients, when functional analyses
ere added to CT coronary categories, the esti-
Table 2. Patient Characteristics as Stratiﬁed by CT CAD Categor
No CAD
(n  183)
N
Demographics
Age, yrs 47.5 9.5
Male 101 (55.2)
Body mass index, kg/m2 28.6 6.0
Risk factors
Diabetes mellitus 13 (7.1)
Hypertension 47 (25.7)
Hyperlipidemia 41 (22.4)
Smoking 76 (41.5)
Family history of CAD 39 (21.3)
TIMI risk score for UA/NSTEMI
0–2 points 180 (98.4)
3–4 points 3 (1.6)
5–7 points 0 (0)
Medications at baseline
Aspirin 49 (26.8)
Beta-blockers 30 (16.4)
Statins 31 (16.9)
ACE-I 17 (9.3)
Any of the above medications 79 (43.2)
Medications at 2-yr follow-up
Aspirin 42 (26.4)
Beta-blockers 34 (21.5)
Statins 29 (18.2)
ACE-I 24 (15.2)
Any of the above medications 77 (48.4)
Values are mean  SD or n (%).
Abbreviations as in Table 1.ated 2-year late MACE rate was low for patientsith no stenosis independent of RWMA (0.6% for
o stenosis or RWMA and 0% for no stenosis with
WMA) and increased with the presence of steno-
is (5.6% for stenosis and no RWMA), and greatest
or patients with both features of stenosis and
WMA (18.5%, log-rank p  0.0001).
In patients who had MACE during the acute
hase, the estimated recurrent event rate was 10% at
years. There was no difference between the rate of
ecurrence in these patients and the rate of late
ACE in those with obstructive CAD but initially
o MACE (8.9%, log-rank p  0.75).
D I S C U S S I O N
In this 2-year follow-up study of the ROMICAT
trial, we evaluated the prognostic value of cardiac
CT for MACE defined as the hard endpoint of
cardiac death, nonfatal myocardial infarction, and
coronary revascularization. The strength of our
study is that it provides 2-year prognostic data, as
obstructive CAD
(n  117)
Obstructive CAD
(n  68) p Value
55.9 10.5 61.6 12.5 0.0001
77 (65.8) 48 (70.6) 0.01
29.2 5.7 29.8 6.5 0.33
9 (7.7) 18 (26.5) 0.0001
50 (42.7) 48 (70.6) 0.0001
57 (48.7) 37 (54.4) 0.0001
58 (49.6) 46 (67.7) 0.0003
26 (22.2) 24 (35.3) 0.04
0.0001
115 (98.3) 52 (76.5)
2 (1.7) 15 (22.1)
0 (0) 1 (1.5)
37 (31.6) 31 (45.6) 0.007
27 (23.1) 27 (39.7) 0.0002
40 (34.2) 32 (47.1) 0.0001
17 (14.5) 22 (32.4) 0.0001
70 (59.8) 55 (80.9) 0.0001
42 (39.3) 32 (51.6) 0.0003
25 (23.4) 34 (54.8) 0.0001
40 (37.0) 33 (53.2) 0.0001
23 (21.5) 24 (38.7) 0.0003
74 (68.5) 48 (77.4) 0.0001ies
onstratified by CT coronary stenosis and functional
ons a
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487results, in acute chest pain patients from a large
prospective observational ED cohort. Unlike
intention-to-treat studies, our study is particularly
unique in that it has a double-blind, prospective,
observational study design (CT results remained
blinded to both caregivers and patients), allowing us
to observe the natural course of this ED cohort
without the influence of the CT results on clinical
outcomes. More specifically, our endpoint, which
includes coronary revascularization, is not driven by
the cardiac CT findings. Given the acceptance of
cardiac CT into clinical practice, such a study
design is unlikely to be possible nowadays.
A promising clinical application of CT appears to
be its use in the early triage of acute chest pain
patients in the ED. Although CT offers results with
a high sensitivity and negative predictive value for
the detection of ACS in ED patients, as previously
reported by our group and others (15,20,25), less is
Table 3. Kaplan-Meier Cumulative Probability of MACE at 30 Da
n (%) 3
CAD categories
No CAD 183 (49.7)
Nonobstructive CAD 117 (31.8)
Obstructive CAD 68 (18.5)
CT stenosis
Stenosis () 300 (81.5)
Stenosis () 68 (18.5)
CT stenosis  regional LV function
Stenosis (), RWMA () 280 (76.1)
Stenosis (), RWMA () 20 (5.4)
Stenosis (), RWMA () 42 (11.4)
Stenosis (), RWMA () 26 (7.1)
Log-rank p value is 0.0001 for all 3 stratiﬁcations.
LV  left ventricular; MACE  major adverse cardiac events; other abbreviati
Table 4. Unadjusted and Adjusted HR of Cardiac CT Features fo
Model 1
HR (95% CI)
CT stenosis
No stenosis 1.00 (reference)
Stenosis 19.84 (7.44–52.89)
CT stenosis  regional LV function
Stenosis (), RWMA () 1.00 (reference)
Stenosis (), RWMA () 24.23 (4.05–145.06)
Stenosis (), RWMA () 13.47 (2.47–73.54)
Stenosis (), RWMA () 124.92 (28.63–545.03)
Model 1  unadjusted Cox proportional hazards model; Model 2  model 1
at 2-year follow-up.
CI  conﬁdence interval; HR  hazard ratio; N/A  not applicable; other abbreviaknown about the prognostic value of CT in this
patient population. Previous studies demonstrated
in different patient cohorts that the absence of
CAD by CT is associated with the absence of
MACE in a follow-up period 60 months
(7,10,11,26). However, these studies were not spe-
cifically designed for evaluation of ED patients with
acute chest pain and the exclusion of ACS. Re-
cently, Hollander et al. (27) reported 1-year out-
come data in ED chest pain patients with a low to
intermediate risk of ACS and concluded that those
with no CAD on CT have a very low likelihood of
cardiovascular events at 1 year. Our study expands
on their results in that we provide 2-year outcome
data, not just 1-year follow-up data. Importantly, in
our patients without CAD on CT, the cumulative
2-year probability for MACE was 0%, which pro-
vides support for at least a 2-year MACE-free
warranty period in patients with normal CT
1 Year, and 2 Years as Stratiﬁed by CT Findings
MACE (Probability)
ays 1 Yr 2 Yrs
) 0 (0) 0 (0)
.4) 4 (3.4) 5 (4.6)
0.6) 18 (26.7) 20 (30.3)
.3) 4 (1.3) 5 (1.8)
0.6) 18 (26.7) 20 (30.3)
.4) 1 (0.4) 2 (0.9)
5.0) 3 (15.0) 3 (15.0)
.8) 3 (7.4) 4 (10.1)
3.9) 15 (57.7) 16 (62.4)
s in Tables 1 and 2.
edicting MACE
Model 2
Value HR (95% CI) p Value HR (95%
N/A 1.00 (reference) N/A 1.00 (referen
0.0001 21.53 (7.68–60.38) 0.0001 16.00 (5.92–43
N/A 1.00 (reference) N/A 1.00 (referen
0.0005 25.64 (4.25–154.68) 0.0004 21.03 (3.50–12
0.003 15.04 (2.67–84.79) 0.002 12.09 (2.20–66
0.0001 138.81 (30.74–626.80) 0.0001 92.49 (20.84–4
sted for being on any baseline medications; Model 3  model 1 adjusted for bys,
0 D
0 (0
4 (3
14 (2
4 (1
14 (2
1 (0
3 (1
2 (4
14 (5r Pr
Model 3
p CI) p Value
ce) N/A
 .22) 0.0001
ce) N/A
6.33) 0.0009
.37) 0.004
 10.54) 0.0001
adju eing on any medicationstions as in Tables 2 and 3.
RWMA, and stenosis with RWMA. MACE  major adverse cardiac event.
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488findings in the ED patient cohort. This represents
50% of our ED patients with acute chest pain,
initial negative troponin, normal or inconclusive
findings on electrocardiography, and low to inter-
mediate risk of ACS and provides further reassur-
ance to ED physicians that early triage using cardiac
CT would be a safe strategy.
The CT diagnosis of obstructive CAD and/or
LV dysfunction have been previously shown to
predict all-cause mortality and future cardiac events,
but these studies included unselected patients with
suspected CAD and were not from a pre-defined
ED cohort (7,9–13,26,28–31). Our results confirm
these other CT studies and provide prognostic
values, which can be specifically applied to the ED
acute chest pain cohort. Patients with nonobstruc-
tive CAD had a nontrivial 4.6% cumulative prob-
ability for 2-year MACE. Patients with coronary
stenosis had a 30.3% cumulative probability of
events at 2 years with a 16-fold increase risk in
MACE after adjustment for medications. If CT
functional data are available, the highest risk of
MACE was in patients with the presence of both
CT stenosis and RWMA with an adjusted 92-
fold increase risk compared with those with
neither feature. Although the presence of no
CAD on CT may lead to an early and safe
hospital discharge of patients (15,32), the detec-
tion of nonobstructive CAD, obstructive CAD,
and RWMA should require a more conservative
triage approach and aggressive management
strategy by caregivers.
Another important finding is that MACE devel-
oped in the majority of patients (n 20, 80%) during
the first 30 days after presentation to the ED and
perhaps the strength of cardiac CT is in its diagnostic
ability during the acute phase. However, it is interest-
ing to observe that once the acute phase has passed,
there remains prognostic utility with a gradient effect
despite the relatively low rate of late MACE that
comprises less than one-third of the cumulative 2-year
event rate in patients with nonobstructive CAD (1.2%
of 4.6%) and obstructive CAD (8.9% of 30.3%).
Patients with MACE during the acute phase had the
highest 2-year rate of late MACE or recurrence rate of
10%, although this was not significantly different from
those with obstructive CAD without initial MACE in
the ED (p 0.75) and must be interpreted cautiously
as exploratory and may be underpowered due to the
low event rate. Most importantly, patients with nor-
mal coronary arteries had an estimated 2-year eventFigure 2. Kaplan-Meier Curves of MACE as Stratiﬁed by Cardiac Computed
Tomography Features
(A) Coronary artery disease (CAD) categories stratiﬁed into no CAD, nonobstruc-
tive CAD, and obstructive CAD. (B) Coronary stenosis was stratiﬁed into no ste-
nosis and stenosis. (C) Coronary and functional computed tomography
categories stratiﬁed into no stenosis or regional wall motion abnormalities, no
stenosis with regional wall motion abnormalities (RWMA), stenosis withoutrate of 0% for late MACE, providing further support
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489of at least a 2-year warranty period for MACE after
CT was performed and showed no CAD.
For cardiac CT to be implemented in the ED, its
use must be incremental to pre-existing readily
available data for the clinicians. The TIMI score
has been the most widely used clinical risk stratifi-
cation score in the low-risk ED patients with acute
chest pain, although it remains less than “perfect”
(23,33,34). With the addition of CT stenosis (cor-
onary anatomy alone) to TIMI risk score, there was
significant improvement in predicting MACE from
0.61 to 0.84 (p  0.0001). Our findings are in
keeping with previous non–ED-based CT prognos-
tic studies that found both coronary atherosclerotic
plaque and stenosis to be predictive of MACE
independent of traditional risk factors and risk
scores (7,12,13,29,30). The addition of func-
tional data to coronary anatomy and clinical
TIMI risk score further improved the discrimi-
natory capacity to 0.91 for predicting MACE and
provides more support of the incremental prog-
nostic value of functional data over coronary
assessment alone (31).
Study limitations. First, this is a prospective, obser-
vational study from a single-center tertiary referral
hospital, which may limit the generalizability of our
results to similar care settings. Thus, our findings
need to be further validated in larger multicenter,
randomized diagnostic trials, although it may not
be feasible anymore to obtain unbiased outcome
data because blinding of CT results may not be
realistic due to the advancement of cardiac CT in
clinical practice. Second, although this study used a
retrospectively gated CT protocol, the newest CT
technology permits frequent use of low radiation
dose, prospectively triggered protocols. In our
study, the radiation dose using electrocardiogram
Table 5. Incremental Predictive Value of Cardiac C Findings Bey
Models HR (95% CI) p
Clinical risk score
TIMI 7.29 (3.04–17.46) 
Clinical risk score  CT ﬁndings
TIMI  stenosis
TIMI 1.77 (0.71–4.40)
Stenosis 17.07 (6.14–47.45) 
TIMI  stenosis  RWMA
TIMI 1.03 (0.41–2.57)
Stenosis 7.48 (2.53–22.13)
RWMA 12.30 (4.50–33.65) 
Abbreviations as in Tables 1 to 4.tube current modulation was 11.4 mSv, which isFigure 3. Kaplan-Meier Curves of Late (>30 Days) MACE as Stratiﬁed by
Cardiac CT Features
(A) Coronary artery disease (CAD) categories stratiﬁed into no CAD, nonob-
structive CAD, and obstructive CAD. (B) Coronary and functional computed
tomography (CT) categories stratiﬁed into no stenosis or regional wall
motion abnormalities (RWMA), no stenosis with RWMA, stenosis withoutond That of Clinical Risk Score
Value C-Statistic
Global
Chi-Square Value
Model Comparisons,
p Value
0.0001 0.61 13.97 N/A
0.84 49.56 0.0001
0.22
0.0001
0.91 78.90 0.0001
0.96
0.0003
0.0001RWMA, and stenosis with RWMA.
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 4 , N O . 5 , 2 0 1 1
M A Y 2 0 1 1 : 4 8 1 – 9 1
Schlett et al.
Prognostic Value of CT in Acute Chest Pain
490still greater than the 2 to 4 mSv published for
prospective triggered protocols (35). Thus, the ben-
efit of the incremental prognostic value of LV
functional data needs to be weighed against the risk
of the additional radiation exposure given to the
patient with retrospectively gated CT scanning
algorithms (36). In contrast, the benefit of prospec-
tively triggered CT scanning algorithms to offer a
much reduced radiation dose needs to be weighed
against the loss of not having LV functional data
(35,37). Further, the assessment of CT wall motion is
qualitative and may be prone to being more subjective.
However, it has been validated in the past against
cardiac magnetic resonance (38). The number of
events was low as expected in this low to intermediate
risk ED population, thus limiting our ability to control
for all potential confounders. Last, although the cu-
mulative data from the ROMICAT trial and other
observational studies suggest that cardiac CT angiog-
raphy is a potentially valuable diagnostic study for useputed tomography for noninvasive
1
1
1
for prediction of(15,32,39), future multicenter, randomized diagnostic
trials in these patients are needed to provide a defin-
itive answer as to whether this modality is indeed a
cost-effective strategy compared with the existing
standard of care.
C O N C L U S I O N S
In acute chest pain ED patients, CT coronary and
functional features predict MACE and have incre-
mental prognostic value beyond clinical risk score.
The absence of CAD on CT provides a 2-year
MACE-free warranty period, whereas coronary
stenosis with RWMA is associated with highest
risk of MACE.
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